135 related articles for article (PubMed ID: 18570058)
21. Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer.
Galvão DA; Taaffe DR; Spry N; Newton RU
Prostate Cancer Prostatic Dis; 2007; 10(4):340-6. PubMed ID: 17486110
[TBL] [Abstract][Full Text] [Related]
22. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
23. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
Wadhwa VK; Weston R; Mistry R; Parr NJ
BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
[TBL] [Abstract][Full Text] [Related]
24. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
Hedlund PO; Damber JE; Hagerman I; Haukaas S; Henriksson P; Iversen P; Johansson R; Klarskov P; Lundbeck F; Rasmussen F; Varenhorst E; Viitanen J;
Scand J Urol Nephrol; 2008; 42(3):220-9. PubMed ID: 18432528
[TBL] [Abstract][Full Text] [Related]
25. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
26. Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells.
Bass R; Perry B; Langenstroer P; Thrasher JB; Dennis KL; Tawfik O; Holzbeierlein J
J Urol; 2009 Feb; 181(2):615-9; discussion 619-20. PubMed ID: 19091346
[TBL] [Abstract][Full Text] [Related]
27. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
Basaria S
J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
[TBL] [Abstract][Full Text] [Related]
28. Inflammation and hypercoagulable state in adult psoriatic men.
Karabudak O; Ulusoy RE; Erikci AA; Solmazgul E; Dogan B; Harmanyeri Y
Acta Derm Venereol; 2008; 88(4):337-40. PubMed ID: 18709301
[TBL] [Abstract][Full Text] [Related]
29. What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer?
Kollmeier MA; Zelefsky MJ
Nat Clin Pract Urol; 2008 Nov; 5(11):584-5. PubMed ID: 18813218
[TBL] [Abstract][Full Text] [Related]
30. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
31. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
32. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
[TBL] [Abstract][Full Text] [Related]
33. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions.
D'Amico AV; Denham JW; Crook J; Chen MH; Goldhaber SZ; Lamb DS; Joseph D; Tai KH; Malone S; Ludgate C; Steigler A; Kantoff PW
J Clin Oncol; 2007 Jun; 25(17):2420-5. PubMed ID: 17557956
[TBL] [Abstract][Full Text] [Related]
34. Transdermal estradiol therapy for advanced prostate cancer--forward to the past?
Ockrim JL; Lalani EN; Laniado ME; Carter SS; Abel PD
J Urol; 2003 May; 169(5):1735-7. PubMed ID: 12686820
[TBL] [Abstract][Full Text] [Related]
35. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
36. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
37. Androgen deprivation therapy for precancerous lesions of the prostate.
Hull D; Bostwick DG
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):285-91. PubMed ID: 18471786
[TBL] [Abstract][Full Text] [Related]
38. Circulating cytokine levels in prostate cancer patients undergoing radiation therapy: influence of neoadjuvant total androgen suppression.
Johnke RM; Edwards JM; Evans MJ; Nangami GN; Bakken NT; Kilburn JM; Lee TK; Allison RR; Karlsson UL; Arastu HH
In Vivo; 2009; 23(5):827-33. PubMed ID: 19779119
[TBL] [Abstract][Full Text] [Related]
39. [Interest of the radiotherapy-hormonotherapy association in the treatment of the high-risk prostate cancer].
Bolla M; Fourneret P; Descotes JL
Bull Cancer; 2008 Dec; 95(12):1213-8. PubMed ID: 19091656
[TBL] [Abstract][Full Text] [Related]
40. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
Singer EA; Golijanin DJ; Messing EM
Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
